Updated: Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G as Treatment for Diverse Metastatic Cancers

SAN MARINO, Calif. and TOKYO, Japan – Dec. 6, 2006 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G(TM) in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy.